Technology | Leads Implantable Devices | May 06, 2019

FDA Approves Attain Stability Quad MRI SureScan Lead from Medtronic

First quad active-fixation left heart lead designed for precise placement and stability

FDA Approves Attain Stability Quad MRI SureScan Lead from Medtronic

May 6, 2019 — Medtronic has received U.S. Food and Drug Administration (FDA) approval for the Attain Stability Quad MRI SureScan left heart lead. Paired with Medtronic quadripolar cardiac resynchronization therapy-defibrillators (CRT-D) and -pacemakers (CRT-P), the Attain Stability Quad lead is the only active-fixation left heart lead, according to the company, and is designed for precise lead placement and stability. The lead will be commercially available in the U.S. in summer 2019.

"Appropriate placement of left heart leads during implantation of CRT devices is critical to achieve the clinical benefits of this therapy. Unfortunately, with present passive-fixation leads, we are not always able to position the lead in an ideal location due to variations in a patient's anatomy and size of the target vessel. We also continue to see lead dislodgements that require reprogramming or repeat surgery for lead repositioning. Having a new active fixation left heart lead allows us to target the ideal location in the patient's vessel with the confidence that the lead will remain in place to allow for continued effective delivery of CRT," said Steven Zweibel, M.D., F.A.C.C., F.H.R.S., C.C.D.S., director of electrophysiology at the Hartford Healthcare Heart and Vascular Institute (Conn.).

CRT is a treatment for heart failure in which an implantable device sends low levels of energy through thin wires, called leads, to stimulate the heart muscle and potentially improve the heart's pumping efficiency. With the introduction of quadripolar leads (leads with four electrodes), physicians can pace from different locations in the heart, but are limited in where they can place the lead. The Attain Stability Quad lead integrates the benefits of a quadripolar lead with a side-helix that allows physicians to fixate the lead precisely in veins of various sizes, including ones not typically amenable to positioning a passive lead. Additionally, patients with this lead and MR-conditional CRT devices are eligible for either 3 Tesla (T) and 1.5T magnetic resonance imaging (MRI) scans, if needed.

For more information: www.medtronic.com


Related Content

News | Leads Implantable Devices

February 24, 2023 — Biotronik announced that it has received CE approval for the Selectra 3D implant tools to include ...

Home February 24, 2023
Home
News | Leads Implantable Devices

January 3, 2023 — The market has been studied for the below mentioned-segmentation and regional analysis for North ...

Home January 03, 2023
Home
News | Leads Implantable Devices

September 20, 2019 — BioTrace Medical Inc. announced the company’s key activities at the 31st annual Transcatheter ...

Home September 20, 2019
Home
News | Leads Implantable Devices

August 5, 2019 — Abbott is recalling the Ellipse Implantable Cardioverter Defibrillators (ICDs) because electrical ...

Home August 05, 2019
Home
News | Leads Implantable Devices

May 13, 2019 — BioTrace Medical Inc. announced the company’s Tempo Lead has obtained CE Mark certification in Europe for ...

Home May 13, 2019
Home
News | Leads Implantable Devices

May 24, 2018 - Medtronic plc announced results from a research study demonstrating the feasibility of a novel approach ...

Home May 24, 2018
Home
News | Leads Implantable Devices

May 18, 2018 — Data on the effectiveness of cardiac resynchronization therapy (CRT) in patients with non-left bundle ...

Home May 18, 2018
Home
News | Leads Implantable Devices

June 20, 2017 — BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral ...

Home June 20, 2017
Home
Videos | Leads Implantable Devices

Bruce Wilkoff, M.D., director of cardiac pacing and tachyarrhythmia devices at Cleveland Clinic, discusses advancements ...

Home May 25, 2017
Home
Technology | Leads Implantable Devices

May 15, 2017 – The U.S. Food and Drug Administration (FDA) has granted market clearance Medtronic’s portfolio of ...

Home May 15, 2017
Home
Subscribe Now